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Background: Obesity during pregnancy is associated with adverse outcomes for the offspring and mother. Lifestyle
interventions in pregnancy such as antenatal exercise, are proposed to improve both short- and long-term health
of mother and child. We hypothesise that regular moderate-intensity exercise during the second half of pregnancy
will result in improved maternal and offspring outcomes, including a reduction in birth weight and adiposity in the
offspring, which may be protective against obesity in later life.
Methods/Design: The IMPROVE (Improving Maternal and Progeny Risks of Obesity Via Exercise) study is a two-arm
parallel randomised controlled clinical trial being conducted in Auckland, New Zealand. Overweight and obese
women (BMI ≥25 kg/m2) aged 18–40 years, with a singleton pregnancy of <20 weeks of gestation, from the
Auckland region, are eligible for the trial. Exclusion criteria are ongoing smoking or medical contra-indications
to antenatal exercise.
Participants are randomised with 1:1 allocation ratio to either intervention or control group, using computer-generated
randomisation sequences in variable block sizes, stratified on ethnicity and parity, after completion of baseline assessments.
The intervention consists of a 16-week structured home-based moderate-intensity exercise programme utilising
stationary cycles and heart rate monitors, commencing at 20 weeks of gestation. The control group do not receive
any exercise intervention. Both groups undergo regular fetal ultrasonography and receive standard antenatal care.
Due to the nature of the intervention, participants are un-blinded to group assignment during the trial.
The primary outcome is offspring birth weight. Secondary offspring outcomes include fetal and neonatal body
composition and anthropometry, neonatal complications and cord blood metabolic markers. Maternal outcomes
include weight gain, pregnancy and delivery complications, aerobic fitness, quality of life, metabolic markers and
post-partum body composition.
Discussion: The results of this trial will provide valuable insights on the effects of antenatal exercise on health
outcomes in overweight and obese mothers and their offspring.
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Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000932864.
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The number of women entering pregnancy in an over-
weight or obese state has increased steadily in developed
countries over the last three decades [1-4], and is also
increasing in developing nations [5]. Maternal over-
weight and obesity are associated with adverse preg-
nancy outcomes, including higher risk of gestational
diabetes, pre-eclampsia, operative delivery, fetal and
perinatal mortality and morbidity, and excessive birth
weight [6,7]. Maternal obesity can also result in long-
term health problems for the offspring, secondary to
perinatal problems and to intrauterine and postnatal
programming effects [7,8], including an increased obes-
ity risk in childhood and adulthood [9].
However, it may be possible to alter programming of
the offspring of obese women to a healthier phenotype
by interventions in pregnancy [10]. There is growing evi-
dence to suggest the prenatal environment may play a
role in programming obesity risk [11]. The link between
maternal and offspring obesity can be explained by the
‘early-life hyper nutrition’ pathway where exposure to
over-nutrition during fetal or early postnatal life may
lead to perturbations of adipogenesis and/or appetite
control mechanisms, creating a propensity to later obes-
ity [8]. There is evidence from animal models that ex-
posure to maternal obesity in utero can lead to offspring
adiposity and cardiovascular and metabolic dysfunction,
which may result from developmentally programmed
hyperphagia, physical inactivity, and altered adipocyte
metabolism [12]. Catalano postulates the existence of a
vicious cycle of obesity, whereby maternal obesity leads
to fetal overgrowth and subsequently post-natal obesity.
Overweight/obese children tend to become obese adults,
and the females, when pregnant, will increase nutrient
supply to the fetus leading in fetal overgrowth in the
next generation [13,14]. Further, it is proposed that off-
spring obesity may be propagated and enhanced in early
life because of the abnormal metabolic milieu in utero in
overweight and obese women [13,14]. This raises the po-
tential of in utero therapy to prevent downstream obesity
and chronic disease obesity in the offspring, via lifestyle in-
terventions targeting behaviours that lead to altered nutri-
ent partitioning and fetal overgrowth [10,13].
The effects of antenatal interventions on offspring out-
come are difficult to establish. Birth weight is the most
easily measured outcome assessing the impact of theintrauterine environment on fetal growth, [11] and we
hypothesize that a reduction in fetal over-nutrition will
be reflected as lower birth weight in offspring of over-
weight and obese mothers. The association between
birth weight and adult weight suggests that there are en-
during effects on later obesity risk [11], and we further
postulate that reduction in birth weight will exert a pro-
tective effect on later obesity risk.
Antenatal exercise may play a positive role on both
maternal and offspring health [15,16], and may be espe-
cially beneficial to the offspring of overweight and obese
women [17]. While evidence on the effects of antenatal
exercise on offspring outcomes (including birth weight)
is inconsistent, there is no evidence of any adverse
impact from moderate-intensity exercise [15,18]. Fur-
thermore, the timing of antenatal exercise may be an im-
portant confounding factor leading to the varying effects
of antenatal exercise on birth weight [17]. There is evi-
dence that antenatal exercise in the second half of gesta-
tion can reduce fetal over-nutrition, birth weight and
adiposity in the offspring, and protect against future
obesity. Baraket et al. found that resistance exercise dur-
ing the second and third trimesters of pregnancy attenu-
ated the effect of increased maternal weight on offspring
birth weight [19]. Clapp demonstrated that continuation
of regular moderate- to vigorous-intensity antenatal ex-
ercise reduced offspring birth weight and subcutaneous
fat mass at birth, with these potentially beneficial effects
persisting up to 5 years of age [20], and that the main-
tenance of a high volume of exercise during mid and late
pregnancy led to a reduction in fetal fat mass [21]. In a
recent randomised controlled trial, we showed that non-
weight-bearing aerobic exercise during the second half
of pregnancy in non-obese women led to a significant
reduction in offspring birth weight and BMI, in associ-
ation with a reduction in metabolic markers of fetal
nutrition [22].
Despite many studies investigating the effects of exer-
cise during pregnancy, the effects of antenatal exercise
in overweight and obese women on both short- and
long-term health of the offspring are largely unknown. A
recent systematic review of randomised controlled trials
of antenatal exercise in overweight or obese women
indicates that antenatal exercise may be beneficial in
limiting gestational weight gain, but there is a lack of
high-quality research evidence to assess the impact on
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are to establish if regular moderate-intensity, non-weight
bearing exercise during the second half of pregnancy in
overweight and obese women will reduce offspring birth
weight and neonatal adiposity, and lead to long-term
beneficial changes such as reduced obesity risk in the
offspring. Secondly, we will explore the effects of ante-
natal exercise on fetal growth and body composition,
maternal pregnancy and delivery outcomes, and mater-
nal and cord blood metabolic and inflammatory markers.
We will collect data on potential confounding/contribu-
tory factors including maternal weight gain, dietary in-
take, overall physical activity, physical fitness and quality
of life indices during pregnancy.
Methods/Design
The IMPROVE (Improving Maternal and Progeny Risks
of Obesity Via Exercise) study is a two-arm parallel ran-
domised controlled clinical trial being conducted in
Auckland, New Zealand. This study is approved by the
Health and Disability Ethics Committee (HDEC) (Minis-
try of Health, New Zealand; 12/NTB/24), and is regis-
tered with the Australian New Zealand Clinical Trials
Registry (ACTRN 12612000932864). Locality approval
has been obtained from the research offices at Auckland,
Counties Manukau, and Waitemata District Health Boards,
as well as relevant Māori research committees within the
Auckland region.
Participants
Pregnant women aged 18 to 40 years with a BMI
≥25 kg/m2 who are carrying a singleton fetus less than
20 weeks of gestation, with gestation confirmed by a dat-
ing scan early in pregnancy, and who are resident in the
Auckland region are eligible for the trial. Exclusion
criteria include ongoing smoking during the current
pregnancy or contra-indications to aerobic exercise in
pregnancy as stated by the American College of Obste-
tricians and Gynaecologists [24].
Recruitment
The Auckland region has a population of approximately
1.4 million and approximately 21,000 births per year. Po-
tential participants are idenified via maternity caregivers,
posters and brochures in health care and community
settings, and newspaper advertisements. All potential
participants are supplied with detailed study information,
and undergo an eligibility assessment. Eligible and willing
participants are registered in the trial before completion
of 20 weeks of gestation, and written informed consent
obtained at the baseline visit. Target rate of recruitment is
8 participants per month, and recruitment is currently
ongoing.Randomisation
After completion of baseline assessments, participants are
randomised in a 1:1 ratio to either intervention or control
group, using stratified blocked randomisation with variable
block sizes of 2 and 4. The two stratification factors
considered are parity (nulliparous/parous) and ethnicity
(Maori/Pacific/New Zealand European or other).
Computer generated randomisation sequences have
been provided by a biostatistician with no clinical in-
volvement in the trial, and are stored securely in a
password-protected computer. Once a participant is reg-
istered to the trial by the recruitment coordinator, a se-
quential study number and randomisation number is
assigned to each participant. The recruitment coordin-
ator does not have access to the randomisation tables.
Group allocation is concealed until completion of base-
line assessments.
Intervention
The intervention group follow a regular structured exer-
cise regime between 20 to 36 weeks of gestation, similar
in nature to a previous antenatal exercise intervention
conducted in non-obese women at our research institute
[22]. The control group do not undergo any antenatal
exercise intervention. Due to the nature of the interven-
tion, participants are un-blinded to group assignment,
following completion of baseline assessments.
The exercise regime consists of home-based stationary
cycling. Magnetic exercycles (Sportop NB600/NB800)
and heart rate monitors (Polar S625X/Polar RS800) are
provided to each participant in the exercise group at
20 weeks of gestation. Exercise intensity is prescribed
using target heart rate zones developed and validated
specifically for overweight and obese pregnant women
[25]. Participants receive instructions on equipment use
and a written exercise prescription with weekly exercise
targets. The 16-week exercise regime consists of 67 exer-
cise sessions, comprising approximately 1500 minutes of
moderate-intensity exercise. The frequency and duration
of prescribed exercise varies over the intervention
period. Participants are instructed to wear their heart
rate monitors to record every prescribed exercise session
they complete during the intervention period. This in-
formation is downloaded from each heart rate monitor
to a computer at the end of the intervention period
utilising Polar Precision Performance software (ProTrai-
ner 5), so that compliance to prescribed exercise sessions
can be assessed.
The intervention commences with 3 exercise sessions
per week and increases to 5 sessions per week. All exer-
cise sessions commence with a 5-minute warm-up on
the stationary cycle at low intensity, maintaining heart
rate below target rate, and concludes with a similar
5-minute cool down.The duration of moderate-intensity
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15 minutes to 30 minutes per session and gradually de-
creases again from 33 weeks of gestation while maintain-
ing the frequency at 5 sessions per week. A qualified
exercise physiologist maintains regular contact with the
exercising participants via phone, email, and home visits.
To increase compliance with exercise, if cycling becomes
unacceptable or uncomfortable with advancing preg-
nancy, participants are encouraged to utilise an alterna-
tive forms of exercise such as brisk walking, while
maintaining same intensity, frequency, and duration of
exercise.
Over the duration of the intervention period, both
groups are free to continue their normal exercise/phys-
ical activity routines and receive standard antenatal care,
and undergo similar study assessments. In addition,
there are no dietary restrictions. Exercise participants
developing obstetric contra-indications to exercise [24]
will discontinue the exercise intervention, but be in-
cluded in the intention to treat analysis.
Primary outcome
Primary outcome is offspring birth weight, measured
in grams (g) and standardized z-score (i.e. corrected for
gestational age and gender) [26]. As there are significant
differences in birth weight between major ethnic groups
in New Zealand, birth weight will also be compared
by customised centiles adjusting for maternal height,
weight, parity, ethnic origin, gestational age at birth, and
gender of the baby [27].
Secondary outcomes
Offspring outcomes include neonatal anthropometry and
body composition, fetal growth measures, cord blood
metabolic markers and newborn complications including
rates of large-for-gestational-age (birth weight >90th
centile) and small-for-gestational-age (birth weight <10th
centile) babies. Maternal outcomes include weight gain,
aerobic fitness, quality of life, metabolic markers, post-
partum weight and body composition, as well as preg-
nancy and delivery outcomes including timing and mode
of delivery and length of hospital stay.
Other aims and outcomes
This study also aims to establish a prospective mother-
offspring cohort for follow-up to determine the long-
term effects of antenatal exercise on anthropometry,
body composition, and obesity risk.
Clinical assessments/Data collection
Each participant visits the Maurice and Agnes Paykel
Clinical Research Unit (Liggins Institute, Auckland) for
three study assessments. The first visit for the baseline
assessment occurs at 19 ± 1 weeks of gestation and thesecond visit at 36 ± 1 weeks of gestation. During the first
visit, participants complete consent forms and fill in
questionnaires on demographic, medical and obstetric
history. The other procedures are similar for both first
and second visits, where each participant’s weight,
height, resting heart rate, resting blood pressure, HbA1c,
and baseline aerobic capacity are assessed by a single in-
vestigator. Blood samples are collected and stored for
metabolic testing. Participants complete a quality of life
assessment questionnaire and the physical activity ques-
tionnaire and 3-day diet records are collected. At the
second visit participants receive a pack with instructions
for collection of cord blood by delivery staff.
During the intervention period, participants in both
groups undergo regular ultrasound scans for research
purposes at 4-week intervals starting from 24 ± 2 weeks
of gestation. Participants are requested to maintain daily
records of any leisure time physical activity/exercise they
engage in between 20 weeks of gestation up to delivery
on exercise diaries provided by the study. Participants
also complete 3-day food intake records and a physical
activity questionnaire at baseline prior to randomisation
and midway though the intervention at a time when ex-
ercise prescription is maximal (32 weeks of gestation), to
assess any group difference in these measures.
The final study visit occurs at 14 ± 2 days after delivery.
Maternal weight and neonatal anthropometry (weight,
length and occipito-frontal head circumference) are re-
corded, and both mother and baby have body composition
assessed by DXA scans. Pregnancy, delivery and newborn
data (including feeding history) are obtained from the par-
ticipants and hospital records. Study exercise diaries and
heart rate monitors are also collected at this point.
Antenatal measures - maternal
Maternal body weight is measured to the nearest 0.1 kg
using calibrated electronic scales (Tanita, USA). Mater-
nal height is measured to the nearest millimetre using
a fixed wall Harpenden Stadiometer (Holtain Ltd.,
Crymych, UK). Resting heart rate and resting blood
pressure are measured using standard protocols [28].
Aerobic fitness testing is carried out using a sub-
maximal graded exercise test on an electronically-braked
cycle ergometer (Schiller, Baar, Switzerland), with simul-
taneous breath-by-breath measurement of expired and
inspired O2 and CO2 gas volumes (ParvoMedics True
One 2400 Metabolic Measurement System, Parvomedics,
Sandy, Utah, USA) to a target heart rate of 150 beats per
minute, as previously described [22]. The test begins with
a workload of 30 W and increases by 10 W every minute
until a target heart rate of 150 beats per minute is reached.
Participants are instructed to maintain a constant cycling
speed at 60 rpm throughout the test. Parameters of inter-
est include time taken to reach the peak heart rate of
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and peak VO2.
Maternal quality of life is measured using a self-
administered questionnaire, the WHO Quality of Life-
BREF (WHOQOL-BREF) version, which consists of a
total of 26 questions in 4 domains [29]. Maternal phys-
ical activity levels are measured using the Pregnancy
Physical Activity Questionnaire (PPAQ). The PPAQ is
self-administered and asks respondents to report the
time spent participating in 32 activities, including house-
hold/caregiving, occupational, sports/exercise, transpor-
tation, and sedentary activities [30]. The total weekly
energy expenditure in MET-h/week is measured. Dietary
data from 3-day food records completed at baseline and
mid intervention are analysed using Foodworks 7 Profes-
sional edition (Xyris Software, Australia). Data are en-
tered into the database by a single investigator blinded
to group allocation, and analysed for total energy intake
as well as% energy from protein, fat, and carbohydrate.
Antenatal measures - offspring
Measurement of fetal growth are performed using stand-
ard obstetric ultrasound techniques by a single investiga-
tor, blinded to group allocation, at a single medical
institution in Auckland (Middlemore Hospital, Counties
Manukau District Health Board). All scans are per-
formed utilising a single Philips IU22 ultrasound scanner
(Philips Ultrasound, Bothell, USA) with 3D capability.
The ultrasound transducer adopted is the Philips curvi-
linear array (C5-1, Philips Ultrasound, Bothell, USA)
while the 3D transducer is a mechanical curved-array
3D abdominal ultrasonic transducer (3D 6–2 Philips
Ultrasound).
Standard growth measurements including biparietal
diameter (BPD), head circumference (HC), humerus di-
aphyseal length (HDL), abdominal circumference (AC),
and femur diaphyseal length (FL) are performed accord-
ing to the protocols published by the Australasian
Society for Ultrasound in Medicine [31]. At each exam-
ination, all measurements are obtained three times from
three separately generated ultrasound images, and then
averaged. The standard measurements are used to calcu-
late estimated fetal weight (EFW) by the Hadlock 4
equation [32]. Scans are recorded electronically for later
analysis of other measures of fetal growth and fat depos-
ition. Soft tissue growth is assessed by measurements
taken from the 3D volume dataset including thigh
circumference (ThC), partial thigh volume (TVol), arm
circumference, (ACirc) and partial arm volume (AVol) as
described by Lee [33]. The 3D volume measurements
are obtained by averaging three measurements from
three manipulations of the one data set offline. Volume
analysis is done offline using Philips QLAB™ software
version 6. Measurements of fetal fat mass are calculatedby taking the total cross-sectional limb area and subtract-
ing the central lean area, as previously described [34].
Between-group comparisons of fetal growth will in-
clude measures of BPD, HC, AC, HDL, FL and EFW at
24, 28, 32, and 36 weeks of gestation. Between-group
comparisons of fetal body composition will include mea-
sures of ThC, TVol, ACir, AVol and estimated fat mass
at 28, 32, and 36 weeks of gestation.
Postnatal measures
Newborn weight, length, and head circumference mea-
sured at birth are obtained from medical records. Data
on Apgar scores at 1 and 5 minutes after birth, neonatal
hypoglycaemia needing intravenous treatment, neonatal
hyperbilirubinaemia requiring treatment, presence of
birth injuries, congenital anomalies, admission to neo-
natal intensive care or special care units, and length of
hospital stay following delivery are also collected. Neo-
natal anthropometry (weight, length, and head circum-
ference) are measured by a single investigator at the
Maurice and Agnes Paykel Clinical Research Unit at
14 ± 2 days after delivery. Neonatal weight is measured
to the nearest 10 g using electronic scales (Tanita 1583,
Tanita Corp). Neonatal length is measured using a
Holtain neonatometer. Occipito-frontal head circumfer-
ence is obtained to the nearest millimetre using a flex-
ible non-stretchable tape. BMI is calculated as weight/
height2 (kilograms/metre2). Ponderal index is calculated
as weight in grams × 100 divided by the cube of length
in centimetres.
Maternal and neonatal body composition and bone
density are evaluated at 14 ± 2 days after delivery by
whole-body dual-energy absorptiometry (DXA, Lunar
Prodigy 2000, General Electric, Maddison, Wisconsin,
USA), by a single investigator at the Maurice and Agnes
Paykel Clinical Research Unit. All scans are analysed
by the same operator, utilising Encore 2007 software
v.11.40.004 including paediatric software packages (GE
Corp., Madison, WI, USA). Quality control checks are
performed on a daily basis prior to scanning, using a
standard block provided by the manufacturer.
Metabolic markers
Maternal blood samples collected at baseline and at the
end of intervention are processed and stored at the
Liggins institute. Venous cord blood is collected at
delivery by the lead maternity carer, who is instructed
beforehand on the procedure. Cord blood samples are
processed within 3 hours of collection and stored at
−80°C at hospital laboratories. We plan to analyse ma-
ternal and cord blood samples at the end of the study.
Parameters that will be assessed include: insulin-like
growth factors I (IGF-I), IGF-II, insulin-like growth
factor binding protein 1 (IGFBP-1), IGFBP-3, leptin,
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(TNF α), insulin, glucose, highly sensitive C-reactive pro-
tein (CRP), triglycerides, total cholesterol, high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C) and free fatty acids. Sex hormone-
binding globulin (SHBG) will also be measured in maternal
samples as a surrogate measure of insulin resistance. Sam-
ples will be preserved for future metabolomics studies.
Statistical considerations
Sample size
Based on a previous exercise intervention performed by
our research group in Auckland using similar method-
ology [22] and using birth weight as the primary out-
come, a total sample size of 100 women (n = 50 per
group) will provide 80% power at 5% level of significance
(two-sided) to detect a group difference of 250 g or
more, assuming a standard deviation of 430 g [22].
Data analyses
Statistical analyses will be performed using SAS version 9.3
(SAS Institute Inc. Cary NC). All statistical tests will be
two-tailed and a 5% significance level maintained through-
out the analyses. Study data are entered into an Excel data-
base, and then imported into SAS for final analysis.
Baseline characteristics
Baseline characteristics will be summarised using descrip-
tive statistics. Continuous variables will be described as
numbers of observed and missing values, mean, standard
deviation, median, minimum and maximum. Categorical
variables will be described as frequencies and percentages.
Results will be presented for each of the two treatment
arms as well as overall. Since any differences between ran-
domised groups at baseline could only have occurred by
chance, no formal significance tests will be conducted.
Treatment effects
Treatment evaluation will be performed on the principle
of intention to treat (ITT), using data collected from
all randomised participants. Analysis of covariance
(ANCOVA) regression models will be used to evaluate the
main treatment effect on the primary outcome between
the two treatment groups, adjusting for parity and mater-
nal ethnicity (i.e. stratification factors). A similar approach
will be used for other continuous secondary outcomes,
with the baseline outcome (if measured) added to the
model as a confounding variable. Model-adjusted means
and their difference between two groups will be estimated
and tested. Logistic regression model will be used for the
analysis of a binary outcome (i.e. yes or no), with associ-
ated odds ratio and 95% confidence interval. In addition
to the intention to treat analysis, a per protocol (PP)analysis will also be undertaken on those participants who
have no major protocol violations.
Reporting will adhere to the CONSORT guidelines for
reporting parallel group randomised trials [35,36].
Discussion
This randomized controlled trial has several unique
characteristics. First, it utilises a non-weight bearing
home-based antenatal exercise intervention, previously
applied to non-obese women [22]. This will enable direct
comparison of outcomes of a similar exercise interven-
tion in obese and lean women. Secondly, the main focus
of this antenatal exercise trial is on offspring health, with
longitudinal assessments of fetal growth and body
composition during the intervention period, as well as
measures of newborn anthropometry and adiposity.
While a number of randomised controlled trials of
prescribed antenatal exercise have been conducted over
the last three decades, their primary focus has been on
maternal health and there is a lack of robust evidence on
the effects of antenatal exercise on offspring health
(18, 23). Furthermore, while there is some evidence
of positive long-term effects of antenatal exercise for
offspring of lean mothers (20), long-term effects on
offspring of overweight or obese mothers appear to have
received little attention. Therefore, this trial also aims to
establish a cohort of overweight /obese mothers and
offspring with well-documented antenatal and perinatal
data to be followed up to determine the long-term ef-
fects of antenatal exercise on offspring and maternal
health. As a result, this study addresses the lack of pro-
spective robust data on the effects of antenatal exercise
on short- and long-term outcomes of mothers and their
offspring (43).
Another feature of this trial is the use of methods to
enhance and monitor compliance to prescribed exercise.
Many antenatal exercise interventions, especially those
involving overweight and obese women have encoun-
tered problems with compliance [37,38]. This may be
partly attributed to the general tendency for physical ac-
tivity levels to decline during pregnancy [39,40], espe-
cially in mothers who are obese [41,42], However, many
previous exercise studies have also failed to report ad-
equately on compliance with interventions [18]. Previous
studies have suggested that home-based exercise inter-
ventions can lead to increased compliance, as they
enable exercise to be undertaken in a comfortable and
familiar environment [43]. Therefore, a home-based inter-
vention was chosen, to enhance feasibility of regular exer-
cise, and improve compliance to the exercise protocol.
Previous home-based stationary cycling interventions in
non-obese [22] and obese [43] pregnant women have re-
ported high acceptance and good compliance levels. Fur-
thermore, during pregnancy, non-weight bearing exercises
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skeletal stress [44], and stationary cycling can be especially
suitable for overweight or obese women, who are likely to
continue to gain extra weight with advancing pregnancy.
In addition, exercise prescription in our study has been
modified to suit sedentary overweight and obese pregnant
women, with gradual progressive increase in frequency
and duration in keeping with recommendations [44], while
maintaining moderate intensity based on target heart rates
specific for this group [25].
While this study has been designed to optimise com-
pliance, it remains essential to have objective assessment
of compliance. This has been absent from many exercise
intervention trials, making assessment of benefits prob-
lematic. In this study, we are using downloadable heart
rate monitors. Not only does this provide evidence of ex-
ercise intensity, but also evidence of compliance that can
be used in outcome analysis.
In summary, the proposed study will provide a platform
to objectively assess a non-weight bearing exercise regime
on overweight and obese women pregnant women, pro-
vide quantitative outcome data on them and their babies,
and lead to an offspring cohort that can be followed
throughout childhood.
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